Company Filing History:
1 out of 3 
1 out of 2 
1 out of 86 
Years Active: 2012-2021
Title: Lluis Ribas De Pouplana: Innovator in Aminoacyl-tRNA Synthetase Inhibitors
Introduction
Lluis Ribas De Pouplana is a notable inventor based in Barcelona, Spain. He has made significant contributions to the field of biochemistry, particularly in the development of novel compounds that target bacterial infections. With a total of 2 patents, his work is paving the way for new therapeutic approaches.
Latest Patents
One of Ribas De Pouplana's latest patents is focused on N-acyl-arylsulfonamide derivatives as aminoacyl-tRNA synthetase inhibitors. This invention relates to novel N-acyl-diarysulfonamides that act as inhibitors of bacterial aminoacyl-tRNA synthetase. These compounds can be utilized as medicines or as components of medicines for treating bacterial infections. Another significant patent involves a screening method for identifying new aminoacyl-tRNA synthetase inhibitors. This method includes several steps, such as obtaining a gene sequence, engineering the gene, cloning it into an expression vector, and analyzing cell growth to identify potential drug candidates.
Career Highlights
Throughout his career, Ribas De Pouplana has worked with various organizations, including Oxford Drug Design Limited and Fundació Privada Parc Científic de Barcelona. His expertise in biochemistry and molecular biology has allowed him to contribute to innovative research and development in the pharmaceutical industry.
Collaborations
Ribas De Pouplana has collaborated with notable professionals in his field, including Aigars Jirgensons and Einars Loza. These collaborations have further enhanced his research and development efforts, leading to advancements in the understanding of aminoacyl-tRNA synthetase inhibitors.
Conclusion
Lluis Ribas De Pouplana is a distinguished inventor whose work in aminoacyl-tRNA synthetase inhibitors is making a significant impact in the fight against bacterial infections. His innovative patents and collaborations highlight his commitment to advancing medical science.